Petrelintide’s 10.7% mean body weight reduction (vs. 1.7% placebo) at 42 weeks in ZUPREME-1 came in under investor expectations: analysts anticipated at least 12%, and Eli Lilly’s rival amylin candidate eloralintide hit about 16% in Phase 2. Roche and Zealand aren’t chasing those numbers. They’re building a different argument.
I noticed the tolerability table when the March release dropped. In ZUPREME-1, petrelintide’s highest dose arm recorded dropout rates no higher than placebo, what Zealand CEO Adam Steensberg calls “the sweet spot for any first-choice medicine.” The totality of the data, as Roche’s Manu Chakravarthy put it ahead of the 2026 ADA conference in New Orleans, includes more than headline weight loss.
Genentech’s enicepatide, a dual GLP-1/GIP agonist and Roche’s other obesity asset, already covers the high end. CT388-103 Phase 2 data show 22.5% placebo-adjusted weight loss at 48 weeks, with 26% of participants shedding more than 30% of their body weight. More than half of patients who entered with a BMI over 30 no longer met the obesity definition at week 48. Petrelintide isn’t competing with that.
The structural read is a two-product segmentation strategy: enicepatide for maximum weight loss (with 5.9% discontinuations versus 1.3% for placebo), petrelintide for the patient who wants 10% without difficult side effects. Novo Nordisk and Lilly aren’t explicitly positioning for that second lane. A combination trial pairing both agents is slated for the second half of 2026, where the real differentiation story could emerge.
Late-breaking ZUPREME-1 data are being presented at ADA 2026 in New Orleans this weekend. Petrelintide Phase 3 is slated to begin second half 2026. Worth watching the Phase 3 design when it drops.
— Rebecca Lauren